We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Eisai Company, Ltd. and Merck & Company today announced that the multiple receptor tyrosine kinase inhibitor LENVIMA® has been approved in Japan for unresectable hepatocellular carcinoma